glp-1 news 2025 november ISPOR 2025: Exploring reasons for discontinuation GLP-1 Drug Side Effects May

Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinsons disease

The global obesity crisis, with over 650 million adults classified as obese by WHO estimates, is creating sustained demand for effective pharmacological interventions

Clinical trials stop after a few years, and some of the currently FDA-approved drugs have only been around for a couple of years

A treatment-related increase in benign thyroid C-cell adenomas was seen in males in 0.25 and 0.75 mg/kg/day liraglutide groups with incidences of 12%, 16%, 42%, and 46% and in all female liraglutide-treated groups with incidences of 10%, 27%, 33%, and 56% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively

Course Format Homestudy Course Syllabus Introduction Semaglutide, Iiraglutide, and Tirzepatide Mechanism of Action Effectiveness of GLP-1 and GIP/GLP-1 RAs for Weight Loss Comparison of Drug Effectiveness Causes of GLP-1 AND GLP/GIP Receptor Failure Common and Mild Adverse Effects Significant Adverse Effects Clinical Considerations for Obesity Treatment Benefits and Risks Choosing the Correct Treatment Lifestyle Changes Duration of Therapy Adverse Effect Monitoring Patient Education Case Study: GLP-1 With Insulin Treatment for Diabetes Summary Author Dana Bartlett, RN, BSN, MSN, MA, CSPI Dana Bartlett is a professional nurse and author